Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
59
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Rapid Disease Progression in a Patient with Advanced NSCLC Harboring a Germline MET Exon 14 Skipping Mutation: A Case Report

Yang Jiao1 Pulmonary and Critical Care Medicine, Changhai Hospital, The Naval Medical University, Guangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-9904-4227
ORCID Icon,
Chen Fang1 Pulmonary and Critical Care Medicine, Changhai Hospital, The Naval Medical University, Guangzhou, People’s Republic of China
,
Yuchen Yang2 Burning Rock Biotech, Guangzhou, People’s Republic of China
,
Lin Shao2 Burning Rock Biotech, Guangzhou, People’s Republic of China
,
Yi Huang1 Pulmonary and Critical Care Medicine, Changhai Hospital, The Naval Medical University, Guangzhou, People’s Republic of China
,
Qinying Sun1 Pulmonary and Critical Care Medicine, Changhai Hospital, The Naval Medical University, Guangzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
&
Yuchao Dong1 Pulmonary and Critical Care Medicine, Changhai Hospital, The Naval Medical University, Guangzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-1910-792X
ORCID Icon show all
Pages 2417-2421 | Published online: 07 Apr 2021

References

  • Tovar EA, Graveel CR. MET in human cancer: germline and somatic mutations. Ann Transl Med. 2017;5(10):205. doi:10.21037/atm.2017.03.64
  • Duplaquet L, Kherrouche Z, Baldacci S, et al. The multiple paths towards MET receptor addiction in cancer. Oncogene. 2018;37(24):3200–3215. doi:10.1038/s41388-018-0185-4
  • Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in Non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol. 2016. doi:10.1200/JCO.2015.63.4600
  • Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26(1):47–51. doi:10.1038/s41591-019-0716-8
  • Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68–73. doi:10.1038/ng0597-68
  • Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. Int J Oncol. 2008;33(2):271–276.
  • Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res. 2009;15(18):5714–5723. doi:10.1158/1078-0432.CCR-09-0070
  • Wu JY, Wu SG, Yang CH, et al. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008;14(15):4877–4882. doi:10.1158/1078-0432.CCR-07-5123
  • Yang JCH, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol. 2020;15(5):803–815. doi:10.1016/j.jtho.2019.12.126
  • Tode N, Kikuchi T, Sakakibara T, et al. Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. Cancer Sci. 2017;108(6):1263–1270. doi:10.1111/cas.13233
  • Wang Z, Cheng Y, An T, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a Phase 2, single-arm, multicentre clinical trial. Lancet Respir Med. 2018;6(9):681–690. doi:10.1016/S2213-2600(18)30264-9
  • Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol. 2015;16(4):e165–72. doi:10.1016/S1470-2045(14)71180-5
  • George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53. doi:10.1038/nature14664
  • Meder L, König K, Fassunke J, et al. Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases. Exp Mol Pathol. 2015;99(3):682–686. doi:10.1016/j.yexmp.2015.11.002
  • Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol. 2019;14(10):1784–1793. doi:10.1016/j.jtho.2019.06.002

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.